Enzyme multiplied immunoassay technique

This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. (March 2008)

This article is written like an advertisement. Please help rewrite this article from a neutral point of view. For blatant advertising that would require a fundamental rewrite to become encyclopedic, use {{db-spam}} to mark for speedy deletion. (May 2009)

Enzyme multiplied immunoassay technique, or EMIT, is a common method for screening urine and blood for drugs, both legal or illicit. First introduced by Syva Company in 1973, it is the first homogeneous immunoassay to be widely used commercially.

A mix and read protocol has been developed that is exceptionally simple rapid. The most widely used applications for EMIT are for therapeutic drug monitoring (serum) and as a primary screen for abused drugs and their metabolites (urine). The US patents covering the major aspects of the method, 3,817,837 and 3,875,011, have expired. While still sold by Siemens Healthcare under its original tradename, EMIT, assay kits with different names that employ the same technology are supplied by other companies. The method is highly reliable and reliance on its results has been upheld by the US Supreme Court.

See also

• Drug tests
• Blood tests
• Screening

References

External links

• MeSH Enzyme+Multiplied+Immunoassay+Technique

This medical article is a stub. You can help Wikipedia by expanding it.

This enzyme-related article is a stub. You can help Wikipedia by expanding it.